In a more recent study, KRAS mutations were identified in 29% of endometriosis-associated endometrioid cancers but in only 3% of tumors in which endometriosis was not identified, supporting the hypothesis that KRAS mutations have an important role only in EAOCs [71]. This evidence concerns the gene KRAS and endometriosis.